Abstract
OBJECTIVE: To explore the clinical experience of split liver transplantation (SLT) as a salvage treatment for acute graft failure (AGF) caused by immune checkpoint inhibitors (ICIs). METHODS: The clinical data of one hepatocellular carcinoma (HCC) patient who underwent two liver transplants were retrospectively reviewed. RESULTS: The patient received multiple PD-1/PD-L1 inhibitor treatments, with the last one administered 16 days prior to the first transplant. On postoperative day 7, there was a rapid increase in transaminases, indicating acute rejection, which was treated with additional Rabbit anti-human thymocyte immunoglobulin(ATG). On day 14, the patient presented with fatigue, shortness of breath, and abdominal distension. An ultrasound revealed reversed portal vein flow and significant liver enlargement. Given the patient's deteriorating condition, a rescue second liver transplant (complete right lobe split liver transplantation with middle hepatic vein bipartition/reconstruction) was performed on day 16. The anti-rejection regimen included ATG, Baliximab, Rituximab, glucocorticoids, and intravenous immunoglobulin (IVIG). Postoperative pathology indicated acute liver failure due to humoral rejection. The patient has since been followed for over 12 months, with stable liver function and no signs of rejection or tumor recurrence. CONCLUSIONS: This case highlights the need for cautious use of ICIs before liver transplantation and supports SLT as an effective option in cases of AGF.